Fennec: Pedmark Approval Can Help Minimize Chemo-Induced Hearing Loss In Pediatric Cancer Patients
Summary
- After two CRLs, PEDMARK has finally been approved for preventing chemo-induced hearing loss in pediatric cancer patients.
- In addition to being both safe and effective, PEDMARK has not shown itself to interfere with the cancer-fighting properties of chemotherapy agents.
- With up to $45M in financing available to fund the launch, FENC has cash to draw on, so the chances of an equity raise seem low.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of FENC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.